Blood Volume and Cardiovascular Dysfunction
1 Hypovolemia and RAAS Dysfunction
Chronic hypovolemia (reduced blood volume) is a well-documented feature of ME/CFS, with direct consequences for oxygen delivery, exercise capacity, and orthostatic symptoms. Paradoxically, the renin-angiotensin-aldosterone system (RAAS) and antidiuretic hormone (ADH) — which normally activate in response to low blood volume — show suppression in ME/CFS patients.
[Miwa, Fujita 2017 (Miwa and Fujita 2017):], This study identified paradoxical down-regulation of volume-regulatory hormones in ME/CFS. Despite documented hypovolemia and reduced cardiac output, plasma aldosterone was 33% lower (104±37 vs 157±67 pg/ml, \(p\)=0.004) and ADH was 33% lower (2.2±1.0 vs 3.3±1.5 pg/ml, \(p\)=0.02) compared to healthy controls (n=14 patients, n=13 controls). Treatment trial: desmopressin (ADH analog) improved orthostatic symptoms in 50% of patients. Certainty: Medium (peer-reviewed, significant findings, but small sample awaiting replication). Implication: Hypovolemia results from central dysregulation of volume-regulatory systems, not excessive fluid loss.
Raj et al. 2005 (Raj et al. 2005): Landmark study demonstrating the “renin-aldosterone paradox” in postural tachycardia syndrome (POTS), a condition overlapping with ME/CFS. Blood volume was markedly reduced (3583±579 vs 4319±578 mL, \(p\)<0.0001), with plasma volume 21% lower (2172±429 vs 2763±437 mL, \(p\)<0.0001). Despite this, plasma renin activity was unchanged and aldosterone was frankly low (7.0±5.3 vs 12.3±6.4 ng/dL, \(p\)=0.01). Strong positive correlation between blood volume and aldosterone (r=0.56, \(p\)=0.001). n=33 POTS patients, n=13 controls. Certainty: High (large sample, replicated, published in Circulation).
Mustafa et al. 2011 (Mustafa et al. 2011): Identified abnormalities in angiotensin II regulation in POTS. Plasma Ang II was significantly elevated (43±3 vs 28±3 pg/mL, \(p\)=0.006), while estimated ACE2 activity was reduced (0.25±0.02 vs 0.33±0.03, \(p\)=0.038). Elevated Ang II may contribute to peripheral vasoconstriction and reduced NO bioavailability. Certainty: Medium-High (peer-reviewed, mechanistic insight into RAAS dysfunction).
Stewart et al. 2006 (Stewart, Glover, and Medow 2006): Increased plasma angiotensin II in low-flow POTS patients related to reduced blood flow and blood volume. Suggests Ang II elevation is compensatory attempt to maintain blood pressure despite hypovolemia, but may contribute to local blood flow dysregulation. Certainty: Medium (mechanistic study linking Ang II to blood volume deficit).
Farquhar et al. 2002 (Farquhar et al. 2002): Early study demonstrating relationship between blood volume and exercise capacity in CFS. Patients had significantly lower peak VO2 consumption with trend toward lower blood volume. Strong correlation between blood volume and peak oxygen consumption, suggesting hypovolemia as physiological contributor to exercise intolerance. Certainty: Medium (established blood volume-exercise link).
van Campen et al. 2018 Campen, Rowe, and Visser (2018): Dual-isotope blood volume measurement in ME/CFS adults. Mean absolute blood volume was 59(8) ml/kg, representing -11(7) ml/kg deficit below reference values. Blood volume reduction correlated with presence of orthostatic intolerance symptoms (n=20). Certainty: High (precise measurement technique, clear clinical correlation).
2 Cardiac Dysfunction and Natriuretic Peptides
Newton et al. 2016 (Newton et al. 2016): CFS patients had significantly reduced cardiac volumes (both end-systolic and end-diastolic) with reduced end-diastolic wall masses. Strong positive correlations between total blood volume, red cell volume, plasma volume and cardiac end-diastolic wall mass. Critically, no relationship between disease length and cardiac/plasma volumes, ruling out deconditioning as sole cause. Certainty: High (cardiac MRI, objective measures, n=42 CFS patients). Implication: Reduced cardiac volumes are primary feature, not secondary to inactivity.
Tomas et al. 2017 (Tomas et al. 2017): Brain natriuretic peptide (BNP) levels significantly elevated in CFS cohort (\(p\)=0.013). Patients with high BNP (>400 pg/mL) had significantly lower cardiac volumes in both end-systolic and end-diastolic measurements (\(p\)=0.05). BNP elevation associated with cardiac dysfunction, not just volume overload. Certainty: Medium-High (established biomarker, cardiac imaging correlation).
3 Endothelial Dysfunction and Vascular Pathology
Scherbakov et al. 2020 (Scherbakov et al. 2020): Peripheral endothelial dysfunction found in 51% of ME/CFS patients vs 20% of healthy controls (\(p\)<0.05). Endothelial dysfunction assessed via flow-mediated dilation. Associated with disease severity and severity of immune symptoms (n=35 patients). Certainty: High (objective vascular measurement, peer-reviewed, ESC Heart Failure). Implication: Vascular pathology contributes to reduced blood flow and tissue perfusion.
Appel et al. 2024 (Appel, Marshall-Gradisnik, and Eaton-Fitch 2024): Comprehensive review of endothelial dysfunction in ME/CFS. Elevated adhesion molecules (ICAM-1, VCAM-1), impaired flow-mediated dilation, chronic inflammatory state contributing to vascular pathology. Links endothelial dysfunction to exercise intolerance and post-exertional symptoms. Certainty: High (systematic review, multiple lines of evidence).
Nunes et al. 2026 (Nunes et al. 2026): Theoretical framework proposing virus-induced endothelial senescence as the unifying mechanistic cause of ME/CFS and long COVID. Central model: acute viral infection triggers endothelial dysfunction and cellular senescence directly (viral endothelial infection) and indirectly (immune-mediated damage). Senescent endothelial cells adopt the senescence-associated secretory phenotype (SASP) — proinflammatory, pro-oxidative, procoagulant, and vasoconstriction-primed — which drives multisystem symptoms. Crucially, the well-documented NK cell dysfunction and T cell exhaustion in ME/CFS prevents clearance of senescent endothelial cells, creating a bidirectional self-sustaining loop: SASP impairs immune function, impaired immune function perpetuates senescence. Tissue-specific effects at the blood-brain barrier (neuroinflammation, brain fog), cerebral arteries (reduced cerebral blood flow), gastrointestinal endothelium (leaky gut, dysbiosis), and skeletal muscle microvasculature (PEM, exercise intolerance) map to distinct ME/CFS symptom clusters. Treatment implications: senolytics (dasatinib + quercetin), senomorphics, NK cell restoration, anticoagulants. Study type: Mechanistic review/theory (no new patient data). Certainty: Medium (peer-reviewed in Cell Death & Disease, Nature Publishing Group; theoretical framework integrating published findings; endothelial senescence not yet directly measured in ME/CFS tissue; causal direction not established). Key limitation: Most supporting evidence from long COVID rather than ME/CFS-specific studies; does not address non-post-viral ME/CFS presentations.
Miller et al. 2020 (Miller et al. 2020): Arterial elasticity significantly increased in Ehlers-Danlos syndrome patients. Central pulse wave velocity significantly lower in EDS (4.73 m/s vs controls), indicating increased arterial elasticity that impairs baroreceptor-mediated blood pressure control. Explains orthostatic intolerance mechanism in EDS and related hypermobility conditions. n=46 EDS patients across multiple subtypes (primarily hEDS). Certainty: High (objective arterial measurements, published in Genes, significant finding). Relevance to ME/CFS: High comorbidity between ME/CFS and hEDS/hypermobility spectrum disorders. Increased arterial compliance reduces effectiveness of baroreceptor responses, contributing to orthostatic intolerance and POTS. Provides vascular mechanism linking connective tissue disorders to autonomic symptoms common in ME/CFS population.
4 Erythropoiesis and Red Blood Cell Function
Streeten DHP, Bell DS. 1998 (Streeten and Bell 1998): Landmark early study measuring circulating blood volume in CFS patients using radiolabeled RBC and plasma volume techniques. Found: red blood cell mass reduced in 93.8% of female and 50% of male ME/CFS patients; plasma volume subnormal in 52.6%. Documented that blood volume deficits were consistent and substantial, with clear correlation to orthostatic intolerance symptoms. Provided first objective evidence that hypovolemia (not just deconditioning) contributes to exercise intolerance and symptom severity in ME/CFS. Certainty: High (gold-standard blood volume measurement technique, clear patient selection, objective methodology). Clinical Implication: Hypovolemia is a primary physiological feature of ME/CFS, not secondary consequence.
Saha et al. 2019 (Saha et al. 2019): Red blood cell deformability significantly reduced in CFS patients using microfluidic measurements. Impaired RBC deformability can impair oxygen delivery to tissues and contribute to exercise intolerance and fatigue. n=20 CFS, n=20 controls. Certainty: Medium-High (novel methodology, replicated findings, published in clinical journal). Implication: Even with adequate RBC count, oxygen delivery may be compromised.
Winkler et al. 2004 (Winkler et al. 2004): Evaluation of serum erythropoietin levels and autonomic function in CFS. Examined potential relationships with anemia and fatigue severity. Certainty: Medium (exploratory study).
Świątczak et al. 2022 (Świątczak et al. 2022): CFS patients show deteriorated iron metabolism: low serum iron, elevated ferritin, reduced transferrin saturation — pattern consistent with inflammatory anemia. Not true iron deficiency but iron sequestration due to inflammation. Certainty: Medium-High (clear pattern, n=multiple cohorts). Link to cytokines: IL-6 and hepcidin drive iron restriction.
Morceau et al. 2009 (Morceau, Dicato, and Diederich 2009): Mechanistic review: pro-inflammatory cytokines (IL-1, IL-6, TNF-\(\alpha\), IFN-\(\gamma\)) suppress erythropoiesis via multiple pathways including hepcidin induction, direct EPO suppression, and shortened RBC lifespan. Relevance to ME/CFS: Elevated cytokines documented in ME/CFS may contribute to functional anemia.
McCranor et al. 2014 (McCranor et al. 2014): IL-6 directly impairs erythroid differentiation in vitro, providing mechanistic link between cytokine elevation and anemia of chronic disease. Certainty: High (mechanistic study, controlled conditions).
Fraenkel 2017 (Fraenkel 2017): Comprehensive review of anemia of inflammation: cytokine-mediated suppression of erythropoiesis, hepcidin-induced iron restriction, shortened RBC survival. Application to ME/CFS: Framework for understanding functional anemia despite normal hemoglobin in some patients.
5 Integrated Mechanisms: The Hypovolemia Cascade
The blood volume deficit in ME/CFS results from convergent mechanisms:
- RAAS/ADH suppression: Paradoxical down-regulation prevents compensatory volume retention (Miwa 2017, Raj 2005)
- Plasma volume reduction: Primary deficit in fluid compartment (Raj 2005: 21% reduction; van Campen 2018: -11 ml/kg)
- Cardiac consequences: Reduced preload → reduced cardiac output → exercise intolerance (Newton 2016)
- Endothelial dysfunction: Impaired vascular regulation → tissue hypoperfusion (Scherbakov 2020)
- RBC dysfunction: Reduced deformability + inflammatory anemia → impaired oxygen delivery (Saha 2019, Świątczak 2022)
- Cytokine-mediated effects: IL-6 and other cytokines suppress erythropoiesis and sequester iron (Morceau 2009, McCranor 2014)
This multi-hit model explains why simple volume expansion (saline infusion) provides only temporary benefit: underlying regulatory systems remain dysfunctional.
Clinical Implications:
- Diagnostics: Dual-isotope blood volume measurement may identify hypovolemic subgroup
- Treatment targets: Desmopressin for ADH-deficient patients (Miwa 2017); fludrocortisone for aldosterone supplementation; management of endothelial dysfunction; optimization of iron availability despite inflammation
- Subtype identification: Not all ME/CFS patients show same degree of hypovolemia; responders to volume-expanding interventions may represent distinct subgroup
Research Gaps:
- Mechanism of RAAS/ADH suppression (central dysregulation? autoimmune?)
- Predictors of desmopressin response
- Longitudinal blood volume changes over disease course
- Relationship between blood volume deficit and PEM severity
- Role of capillary permeability in plasma volume loss